2Suppliers
6Customers
2Debt Items
12Related Chains

uniQure N.V. Suppliers

TickerNameConfidenceEvidence
GENEZEN GENEZEN 90% Pursuant to the CSA, Genezen manufactures and supplies CSL Behring’s commercial demand for HEMGENIX® on our behalf.
MGX Metagenomi Therapeutics, Inc. 72% Reciprocal relationship from MGX graph: evenue and achieve or maintain profitability; • the level of taxes that we are required to pay; and • the availability of capital. Any reduction in reimburseme…

uniQure N.V. Customers

TickerNameConfidenceEvidence
CSL-BEHRING CSL-BEHRING 90% We are contractually obligated to supply the Product until such time that these capabilities are transferred to CSL Behring or its designated contract manufacturing organization.
MGX Metagenomi Therapeutics, Inc. 72% Reciprocal relationship from MGX graph: Reciprocal relationship from QURE graph: Reciprocal relationship from MGX graph: evenue and achieve or maintain profitability; • the level of taxes that we are…
COMPANY-INCORPORATED COMPANY-INCORPORATED 62% t we own or have licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; ● our competitors might conduct activities in countries where we do not have patent…
CSL-BEHRING-INC CSL-BEHRING-INC 62% 2.5 million (presented within Other expense in the Consolidated Statement of Operations and Comprehensive Loss) was recorded during the year ended December 31, 2024. ​ 131 ​ Table of Contents The Com…
GUGGENHEIM-SECURITIES-LLC GUGGENHEIM-SECURITIES-LLC 62% t we own or have licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; ● our competitors might conduct activities in countries where we do not have patent…
LEERINK-PARTNERS-LLC LEERINK-PARTNERS-LLC 62% t we own or have licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; ● our competitors might conduct activities in countries where we do not have patent…

uniQure N.V. Debt Obligations

InstrumentDescriptionConfidenceEvidence
QURE-DEBT Debt stack $545.7M 90% Market cache reports total debt of $545.7M.
QURE-DEBT-12027 Warrants outstanding: 12 90% xbrl warrant detail from xbrl 2025-12-31.

uniQure N.V. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for uniQure N.V..

uniQure N.V. Ownership

HolderNameConfidenceEvidence
QURE-OWNER-AVORO-CAPITAL-ADVISORS-LLC Avoro Capital Advisors LLC 90% 13F overlay lists Avoro Capital Advisors LLC as top holder; 222 tracked holders.

uniQure N.V. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CRBU Caribou Biosciences, Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CRSP CRISPR Therapeutics AG 100.00 2
SGMO Sangamo Therapeutics, Inc. 100.00 2
IONS Ionis Pharmaceuticals, Inc. 100.00 2
LLY Eli Lilly and Company 100.00 2
NTLA Intellia Therapeutics, Inc. 100.00 2
MYGN Myriad Genetics, Inc. 50.00 2
IONIS IONIS 50.00 2
SNYNF Sanofi 50.00 2
MGX Metagenomi Therapeutics, Inc. 36.29 1 ['customer', 'supplier']